Overview of Diatabs Reformulated

Property	Description
Active Ingredient	Loperamide Hydrochloride
Form	Oral Solid Preparation (Tablet/Capsule)
Pharmacological Class	Antidiarrheal / Antimotility Agent
General Purpose	Symptomatic Relief of Diarrhea
Origin	Synthetic Piperidine Derivative

What Type of Medicine is Diatabs Reformulated?

Diatabs Reformulated is a medicinal product whose active ingredient is Loperamide Hydrochloride, classified as a potent antidiarrheal agent belonging to the pharmacological class of antimotility agents. This compound is a synthetic piperidine derivative, utilized for the symptomatic management of disrupted bowel function. The active component, Loperamide, is clinically recognized as a first-line treatment for non-specific diarrhea, supported by extensive pharmacological studies. It functions to decrease the number of stools and make them less watery. The product is typically presented in oral solid preparations, such as a tablet or capsule, and contains Loperamide as the sole active ingredient.

The General Purpose of Diatabs Reformulated

The general purpose of taking Diatabs Reformulated is to achieve symptomatic relief by helping to control episodes of diarrhea. It works by reducing the rapid rate at which contents move through the intestine, thereby helping the body manage the associated fluid loss. By acting as a peripheral \mu-opioid receptor agonist, Loperamide Hydrochloride slows down the muscular contractions responsible for propelling waste, a key action that defines its general therapeutic benefit. This action supports the restoration of a more regulated pace for the digestive process and helps improve stool consistency, often used in scenarios where immediate relief from frequent bowel movements is sought.

Diatabs Reformulated vs. Previous Formulations

The designation "Reformulated" specifically refers to the product now being defined by its active composition of Loperamide Hydrochloride. This distinction is important because previous or alternative formulations of Diatabs utilized different substances, such as Attapulgite, which acts as an adsorbent rather than an antimotility agent. The current Diatabs Reformulated operates on a pharmacological principle that directly modifies intestinal function, representing a compositional shift to a targeted antidiarrheal agent.

Regulatory References

MedlinePlus: Loperamide

What side effects are possible with Diatabs Reformulated?

Diatabs Reformulated, which contains Loperamide Hydrochloride, has a documented safety profile derived from clinical use and regulatory review, with adverse reactions classified primarily by frequency and affected organ system. This information is consistent with regulatory documents such as the FDA Prescribing Information and the European Summary of Product Characteristics.

Frequency and System Classification

Adverse reactions are grouped according to their incidence. Effects classified as Common (occurring in 1/100 to <1/10 patients) frequently involve the digestive and nervous systems. These include constipation, headache, dizziness, nausea, and flatulence. Reactions classified as Uncommon include abdominal pain, dry mouth, and somnolence (drowsiness).

Serious Adverse Reactions and Safety Constraints

The regulatory label documents rare but serious adverse reactions and critical safety constraints. Serious events reported include Toxic Megacolon (in specific underlying patient conditions) and severe cutaneous reactions, such as Stevens-Johnson syndrome. Serious Cardiac Arrhythmias (e.g., QT prolongation) are officially noted, particularly when the medicine is used in doses that exceed the recommended limits.

Population-Specific Notes

The product is contraindicated for use in children under 2 years of age due to the risk of serious adverse reactions, including severe cardiac events. Caution is also noted for patients with severe hepatic impairment due to the potential for increased systemic exposure. Official labeling restricts use in situations where the inhibition of bowel movement (peristalsis) must be avoided, such as in cases of significant abdominal distension or paralytic ileus.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Diatabs Reformulated (Loperamide Hydrochloride) may result in severe, potentially life-threatening systemic toxicity that is officially documented to primarily affect the central nervous system and the heart.

System Affected	Documented Overdose Manifestations
Cardiovascular	Signs include QT interval prolongation, ventricular arrhythmias, Torsades de Pointes, and the most severe reported outcomes of cardiac arrest and sudden death.
Central Nervous System	Manifestations of CNS depression such as somnolence, stupor, and an inability to wake or react normally (unresponsiveness), alongside miosis.
Gastrointestinal	Severe complications including paralytic ileus and toxic megacolon are listed in official regulatory labeling.

When Immediate Medical Help is Required Official regulatory documents mandate that you seek immediate medical attention for specific overdose signs. Urgent medical help must be sought if the patient experiences fainting (syncope), a rapid or irregular heart rhythm, or is unresponsive. Contacting a Poison Control Center or emergency services (Call 911) is strictly required under these conditions.

Management and Special Considerations Management of overdose involves immediate drug discontinuation and initiating symptomatic and supportive care, including necessary therapy to manage cardiac arrhythmias and continuous ECG monitoring. Naloxone may be administered for CNS depression, although repeated doses may be required. Patients with hepatic impairment must be closely monitored for signs of CNS toxicity due to potential increased exposure.

Therapeutic Uses of Diatabs Reformulated

What Diatabs Reformulated treats: main uses and benefits

Diatabs Reformulated is used to provide temporary relief of common, non-specific symptoms associated with general gastrointestinal discomfort. The medicine is indicated for the relief of common symptoms, specifically stomach cramps, general abdominal pain, and diarrhea. These indications are typically associated with common, self-limiting clinical scenarios, such as instances of traveler’s diarrhea or mild gastrointestinal upset.

The primary benefit is the temporary, non-specific relief of these uncomfortable symptoms, which may support a return to normal daily routines. Relieving symptoms of acute diarrhea is a key part of supporting patient comfort.

Quick Fact: Relief for Acute, Non-Specific Diarrhea

Eligibility and Restrictions for Use

Who can and cannot use Diatabs Reformulated?

The eligibility for using Diatabs Reformulated (Loperamide Hydrochloride) is strictly defined by regulatory authorities and is based on age, underlying conditions, and physiological status.

Populations Absolutely Contraindicated

Children under 2 years of age must not use this medicine due to safety risks.
Patients with acute dysentery (characterized by bloody stools or high fever), acute ulcerative colitis, or specific bacterial enterocolitis are strictly prohibited from use.
Use is also forbidden for abdominal pain without diarrhea.

Conditional and Restricted Use

Adults and adolescents (12 years and over) are approved for use under standard conditions.
Patients with hepatic impairment (liver function limitations) must use the medication with caution and require close monitoring.
Individuals with known cardiac risk factors should avoid use.
In pregnancy, use is restricted and permitted only if the potential benefit justifies the risk, reflecting its Pregnancy Category C status.
The medicine is not recommended for mothers who are breastfeeding.
Therapy must be stopped immediately if abdominal distention or constipation develops.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacokinetic and Pharmacodynamic Interactions

The interaction profile of Diatabs Reformulated (Loperamide Hydrochloride) is defined by both pharmacokinetic and pharmacodynamic effects, as documented in official government labeling. Concomitant use with specific medicines or products may significantly alter the systemic exposure of Loperamide or pose additive risks.

Documented Exposure-Altering Interactions

Loperamide is a substrate for the efflux transporter P-glycoprotein (P-gp) and is metabolized by the liver enzymes CYP3A4 and CYP2C8. Co-administration with potent P-gp inhibitors (e.g., Quinidine, Ritonavir) or inhibitors of CYP3A4 and CYP2C8 (e.g., Itraconazole, Gemfibrozil) is documented to result in a substantial increase in Loperamide plasma concentrations. Conversely, Loperamide itself has been shown to reduce the exposure of certain co-administered P-gp substrate medicines, such as Saquinavir.

Interaction-Related Restrictions and Considerations

The co-administration of Loperamide with other medicinal products or herbal supplements known to prolong the QT interval is advised against due to a documented risk of serious cardiac adverse events. Additionally, alcohol may increase the risk of central nervous system effects, such as drowsiness or dizziness. Specific caution is noted for patients with hepatic impairment, as their reduced metabolism of Loperamide can lead to increased systemic exposure, a condition requiring close monitoring.

Mechanism of Action

Modulation of Peripheral Neurotransmission in the Gut

The mechanism of Loperamide begins with its role as an agonist at the mu-opioid receptors (mu-opioid) located primarily on the nerve endings within the intestinal wall's myenteric plexus. This targeted interaction suppresses the release of excitatory chemical messengers, such as acetylcholine and prostaglandins, that mediate intestinal smooth muscle contraction.

Reducing Intestinal Motility and Transit Velocity

The molecular action of suppressing nerve output translates directly into reduced activity of the intestinal smooth muscles. By dampening the signals that drive propulsive peristalsis, the drug increases the transit time of contents through the intestine. This slower movement facilitates the subsequent step that facilitates fluid absorption.

Enhancing Water and Electrolyte Reabsorption

The drug also exerts a complementary antisecretory effect by promoting the net absorption of water and electrolytes from the contents back into the body, particularly influencing chloride ion transport across the intestinal mucosa. The combined effect of slowing movement and enhancing reabsorption leads to a physiological state of diminished fluid content and increased viscosity of intestinal matter.

Dosage and Administration Information

How to Use Diatabs Reformulated

Administration Route and Forms

The approved route for Diatabs Reformulated (Loperamide Hydrochloride) is strictly oral administration. The medicine is supplied as oral solid preparations, such as tablets or capsules, and may also be available in various oral liquid preparations. Solid dosage forms must be swallowed whole with fluid. If a liquid preparation is used, it should be shaken well before measurement.

Official Dosing and Frequency

The administration of the medicine follows an event-driven pattern for managing acute, non-specific episodes. The standard adult initial dose is set at 4 mg, followed by a subsequent dose of 2 mg taken after each unformed stool. Use is subject to a strict maximum daily dose. This limit is typically 8 mg for self-medication (OTC) but may be increased up to 16 mg per day when administered under the supervision of a healthcare professional.

Procedural Constraints and Duration

Loperamide Hydrochloride can be administered with or without food. The official use protocol mandates that the medicine must be utilized as an adjunct to appropriate fluid and electrolyte replacement therapy. For non-prescription acute use, treatment is generally constrained to a maximum duration of 48 hours (two days). The dosage for chronic conditions is established by adjusting to the lowest effective daily maintenance dose, which is administered in divided doses. Official labeling consistently advises that the medicine is not recommended for use in children under two years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diatabs Reformulated

The research foundation for Loperamide Hydrochloride, the active ingredient in Diatabs Reformulated, focuses on clinical evaluation primarily through controlled trials. This overview describes the research that has been conducted and what remains to be fully explored, adhering to findings reported in official and scientific sources.

Evidence Base for Acute, Non-Specific Diarrhea

Research for this use, which involves conditions characterized by acute or disruptive episodes, has largely relied on controlled trials and subsequent Meta-analyses. In these trials, studies were conducted during periods of increased symptom activity and were designed to compare outcomes related to Loperamide against a placebo (an inactive substance).

Researchers monitored outcomes related to functional imbalance, such as the frequency of bowel movements and the consistency of stool. The findings describe patterns observed in the studies where the measured frequency of daily bowel movements was associated with a difference compared to the control groups. Research highlights changes measured during the study period, helping to contextualize how patients reported their experience over defined time intervals.

Evidence Structure for Chronic Symptomatic Management

Studies have also explored the active ingredient in conditions involving periods of heightened symptoms, such as certain types of chronic diarrhea or in populations with an ileostomy or colostomy. These studies typically involve smaller patient groups and may use different study designs, such as cross-over trials.

In these research scenarios, the studies explored outcomes reflecting daily functioning or activity level, such as the total volume of stoma discharge or the daily number of bowel movements. Findings indicate patterns related to monitored outcomes of functional imbalance during the study period.

Research Gaps and Uncertainty

The research landscape highlights several areas where certainty remains low or data are still emerging. Comparative evidence is lacking for the active ingredient against all possible alternative treatments. Additionally, while studies contribute to the broader evidence landscape, there is limited information for long-term outcomes, especially regarding the full spectrum of specific chronic conditions. Evidence related to children under the age of 2 years remains limited. The data show patterns related to symptom patterns in the populations studied, but these findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Diatabs Reformulated (FAQ)

Q: How quickly can I expect Diatabs Reformulated to start working?

A: Pharmacological data describes the onset of the medicine's action as generally occurring within about one hour after you take an oral dose. This information is based on studies of how the drug is processed by the body.

Q: Does Diatabs Reformulated work immediately?

A: The full effect of the medicine is not considered immediate. Studies indicate that the onset of action is generally described as about one hour, with the maximum concentration in the blood being reached in approximately five hours.

Q: How long does the effect of Diatabs Reformulated typically last?

A: Pharmacological studies indicate that the apparent half-life of the active ingredient is approximately 10.8 hours. The duration of its effect is described in medical literature as lasting up to three days.

Q: Can Diatabs Reformulated be taken with common pain relievers like ibuprofen?

A: Official medication interaction checkers have not found a direct pharmacokinetic interaction between Loperamide and Ibuprofen (a type of nonsteroidal anti-inflammatory drug). However, the overall interaction profile is complex, and consultation with a healthcare professional is always part of safe medicine use.

Q: Is Diatabs Reformulated okay for people with kidney problems?

A: Although the medicine is primarily processed by the liver, official documents note that antiperistaltic agents are used with extreme caution in patients who have renal dysfunction (kidney problems). This reflects the need for careful supervision in such cases.

Q: Can older adults use Diatabs Reformulated safely?

A: The medicine is approved for use in adults, defined as ages 12 and over. Official labeling does not define a separate dose or specific restriction for use in the elderly population, provided they do not have other listed risk factors, such as underlying cardiac or liver issues.

Q: Does taking Diatabs Reformulated affect my blood pressure?

A: Official adverse event reporting for the active ingredient primarily documents rare but serious effects related to heart rhythm, such as QT prolongation, especially when taken in high doses. The regulatory label does not specifically cite blood pressure changes (either high or low) as a common or uncommon adverse reaction.

Q: Is the research evidence for Diatabs Reformulated reliable?

A: The evidence supporting Loperamide Hydrochloride is primarily derived from clinical research. This includes controlled trials and subsequent meta-analyses, which are the types of evidence considered by regulatory bodies during drug review.

Q: Do experts recommend Diatabs Reformulated for its intended use?

A: The active ingredient, Loperamide, is widely recognized in authoritative medical literature as a first-line therapy for the symptomatic management of non-specific diarrhea. This reflects its established role in clinical practice for controlling acute episodes.

Q: Is Diatabs Reformulated a prescription drug or available over-the-counter?

A: According to official labeling, the medicine is authorized for both over-the-counter (OTC) self-medication at a strict maximum daily dose and is available by prescription at a higher dose when supervised by a healthcare professional.

Q: Is it possible to develop a tolerance to Diatabs Reformulated over time?

A: Tolerance is not a commonly cited effect in official labeling for routine therapeutic use. Official documents describe the management of chronic conditions by adjusting to the lowest effective maintenance dose. However, specific warnings do exist regarding the potential for misuse or abuse when the drug is taken in very high doses.

Q: Are there any known long-term effects of using Diatabs Reformulated?

A: Official research documents note that while the evidence base for acute use is well-established, there is limited information available specifically regarding the long-term outcomes associated with extended use of the active ingredient.

Q: What should I do if I experience an unexpected reaction to Diatabs Reformulated?

A: Regulatory documents describe that patients are advised to discontinue use if symptoms worsen, diarrhea lasts for more than two days, or unexpected signs such as abdominal swelling occur, and to consult a healthcare professional at that time.

Q: Does Diatabs Reformulated contain any common allergens like gluten or lactose?

A: The official DailyMed label lists all the medicine’s inactive ingredients, also known as excipients. These can include substances like starches and cellulose. The full list of inactive ingredients on the product's authorized labeling can be reviewed by patients with specific allergen concerns, such as gluten or lactose sensitivity.

Q: Why is Diatabs Reformulated available in different strengths or forms?

A: The medicine is available in different strengths and forms, such as solid tablets and liquid preparations, to accommodate variations in required doses. These variations are regulated by the patient’s age and whether the use is for self-medication (OTC) or under prescription.

Q: How is the reformulated version different in how it works in the body?

A: The reformulated product's active ingredient, Loperamide Hydrochloride, works by modulating peripheral neurotransmission in the gut, which slows down intestinal movement. This represents a distinct mechanism of action compared to the previous formulation, which functioned as an adsorbent.

Q: Can taking Diatabs Reformulated make other conditions I have worse?

A: Regulatory documents confirm that the medicine is strictly contraindicated for patients with certain underlying conditions, such as acute dysentery or acute ulcerative colitis, due to the documented risk of serious adverse events like Toxic Megacolon. Official caution is also noted for those with hepatic impairment.

Q: Where can I find the official regulatory information about Diatabs Reformulated?

A: Official regulatory information, including the full FDA label (Prescribing Information) and Drug Approval Packages, is publicly available. You can typically find this documentation on government websites such as the DailyMed database maintained by the NIH.

Q: Is Diatabs Reformulated a product that has been approved by the FDA (or equivalent authority)?

A: Yes, Loperamide Hydrochloride, the active ingredient, has undergone the required New Drug Application (NDA) process and has received official approval from the FDA for use as an anti-diarrheal agent.

Q: Does Diatabs Reformulated interact with antacids?

A: Official interaction checkers have not identified a direct interaction between Loperamide and common antacids. Official documents state that, as is generally advised for all oral solid medicines, maintaining a temporal separation (a time gap) when taking both an antacid and an oral solid preparation is often discussed.

Q: What are the main findings from the clinical trials for Diatabs Reformulated?

A: Clinical trial findings for the active ingredient primarily focused on comparing outcomes related to functional imbalance. These studies examined the measured difference in the frequency of bowel movements and improvement in stool consistency in treated groups compared against a placebo.

Q: Is there a risk of becoming dependent on Diatabs Reformulated?

A: Official regulatory warnings exist regarding the potential for misuse. The potential for abuse has been documented when the active ingredient is used in doses that substantially exceed the recommended therapeutic limits, which is a key safety constraint.

Q: Has the main purpose of the drug changed since it was reformulated?

A: No, the general purpose of the medicine—which is the symptomatic relief and control of diarrhea—remains the same following the compositional shift to Loperamide Hydrochloride. The change was in the active ingredient and mechanism, not the intended clinical use.

How should Diatabs Reformulated be stored and disposed of?

How to Store and Dispose of Diatabs Reformulated?

This medicine must be stored and disposed of strictly according to regulatory label requirements to ensure stability and public safety.

Detail	Official Regulatory Requirement
Storage Temperature	Store at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F) [1.1, 1.2].
Environmental Protection	Keep the product protected from moisture and light, and do not refrigerate [1.1, 4.1].
Container Rules	Store the tablets in the original container with the lid tightly closed [4.2].
Child Protection	The product must be kept out of the reach and sight of children [1.3, 4.2].

For disposal, the primary recommendation is to use a drug take-back program or mail-back envelope when available [2.1]. If no program is available, the medicine must be removed from its original packaging, mixed with an unpalatable substance (like dirt or used coffee grounds), placed into a sealed container, and then thrown into the household trash [2.1]. Do not flush the medication down the sink or toilet [2.1].

Diatabs Reformulated